Research to be published in Science on April 29, 2016 shows how cash-hungry patent trolls are squelching innovation when the American economy depends on it more than ever. What should be done?
The new study, co-authored by Professor Lauren Cohen of Harvard Business School, Professor Umit Gurun of the University of Texas at Dallas, and Dr. Scott Duke Kominers, a Junior Fellow at the Harvard University Society of Fellows, examines the sharp rise in patent litigation in the United States during the past decade, with 2015 marking one of the highest patent lawsuit counts on record.
In theory, the rise in patent litigation could reflect growth in the commercialization of technology and innovation, as lawsuits increase proportionately as more and more companies turn to intellectual property (IP) protection to safeguard their competitive advantages. In reality, however, it’s a very different story. The authors point out that the majority of recent patent litigation has been driven by “nonpracticing entities” (NPEs) – firms that generate no products but instead amass patent portfolios just for the sake of enforcing IP rights.
Cohen, Gurun, and Kominers discuss new, large-sample evidence adding to a growing literature that suggests that NPEs—in particular, large patent aggregators—on average act as “patent trolls,” suing cash-rich firms, seemingly irrespective of actual patent infringement.
Patent trolling has a negative impact on innovation activity at targeted firms. Cohen, Gurun, and Kominers estimate that after settling with NPEs (or losing to them in court), companies on average reduce their research and development (R&D) investment by more than 25 percent. These results, Cohen, Gurun, and Kominers say, indicate a need to change U.S. intellectual property policy, particularly to screen out trolling early in the litigation process.
Although since 2010 the U.S. Congress has considered more than a dozen bills aiming to reduce patent trolling, most of the proposed policy changes focus on after-the-fact punishments for bringing lawsuits that are declared to be frivolous (or “extraordinary”) after court proceedings.
For example, H.R. 9, the “Innovation Act,” which is currently on the docket, provides for mandatory fee-shifting for patent lawsuits that the courts determine are not “reasonably justified.” In reality, however, the average costs of patent litigation are large ($1 million to $4 million) and the process is drawn out. Even with the prospect of post-trial fee shifting, patent litigation targets may thus find it cost-effective and less disruptive to simply settle with NPEs, even in unfounded lawsuits. According to the authors, this is not a sufficient solution.
So what should be done? Cohen, Gurun, and Kominers say that policies should screen out trolling at or before the time of patent assertion. The authors recommend advance review procedures that would provide preliminary evaluation as to whether the plaintiff’s infringement claims are reasonable, and whether the asserted patents are of high quality. Such advance review could cripple trolling, they conclude – pre-litigation review can separate good NPEs (and, more generally, good patent lawsuits) from bad. Legitimate infringement claims will be encouraged, whereas trolling will be screened out. This would greatly benefit innovative companies and help them propel the U.S. economy to greater heights.
The Latest on: Patent Aggregators
[google_news title=”” keyword=”Patent Aggregators” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Patent Aggregators
- UATP Receives Second Patent Approval for Innovative Alternative Form of Payment Processing Solutionon May 7, 2024 at 9:59 am
UATP, the global payment network that enables organizations to simplify payment processes to expand their payment capabilities, has received approval from the US Patent and Trademark Office (USPTO) ...
- Fingerprint Cards strikes deals for biometric wearable, IP licensingon May 6, 2024 at 5:48 pm
Infrafon is collaborating with Fingerprint Cards on the development and launch of a new multifactor authentication solution.
- 5 Steps to Patent an Ideaon May 6, 2024 at 4:59 pm
Think you've got a million-dollar idea? You're not alone. There's always a few people out there at any moment, convinced they've got the next big app or the next popular product, while ...
- Fingerprint Cards AB (publ) signs patent license agreement with major global firm, the first of its kind in the company’s historyon May 6, 2024 at 5:00 am
Fingerprints today announced that the company has signed a patent license agreement with a major global company as the licensee. This represents a milestone as Fingerprints’ first-ever patent license ...
- FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugson April 30, 2024 at 3:44 pm
The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
- Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolioon April 29, 2024 at 7:01 pm
Royalty aggregators like Royalty Pharma, Ligand, and XOMA are revolutionizing biotech by providing upfront cash for R&D. Read more on LGND stock here.
- Cancer Drugs: Strategies For Patenting Antibody-Drug Conjugate Inventionson April 29, 2024 at 5:00 pm
The patent challenger, therefore ... 2) Could the selected payload interfere with the properties of the antibody or vice versa (e.g., cause aggregation, lower solubility, or changes to important ...
- Velocipede Patentson April 21, 2024 at 5:00 pm
Smith agt. Calvin Witty was heard. The plaintiff charged that the defendant had infringed on his patents for improvements in velocipedes, and prayed that an injunction be granted. He averred that ...
- Jury orders Amazon to pay $525 million to Chicago tech firm for patent infringementon April 11, 2024 at 4:28 pm
CHICAGO (CBS) --A federal jury in Chicago has awarded $525 million in damages to a Chicago-based tech firm, after finding Amazon Web Services infringed on three of the company's patents.
- Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on ...on April 7, 2024 at 11:00 pm
This patent claimed deuterated and other isotopic ... 9 Kocis P, et al: Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular ...
via Bing News